Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs

BACKGROUND: This study aimed to describe the clinical and cost-effectiveness evidence supporting reimbursement decisions of new cancer drugs and analyze the influence of trial characteristics and the cost per quality-adjusted life years (QALYs) on the likelihood of reimbursement in Sweden. PATIENTS...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauca Strand, G., Bonander, C., Jakobsson, N., Johansson, N., Svensson, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588887/
https://www.ncbi.nlm.nih.gov/pubmed/36037568
http://dx.doi.org/10.1016/j.esmoop.2022.100569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588887/
https://www.ncbi.nlm.nih.gov/pubmed/36037568
http://dx.doi.org/10.1016/j.esmoop.2022.100569

Ejemplares similares